Atossa Genetics Announces Preliminary Results from Male Phase 1 Study of Topical Endoxifen
***All Objectives Successfully Met*** Conference Call to Be Held Today at 10 am Eastern Time SEATTLE, Sept. 13, 2018 (GLOBE NEWSWIRE) -- Atossa Genetics Inc. (NASDAQ:ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and …